Dr. Carlson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
# Division
Milwaukee, WI 53226Phone+1 414-805-6800Fax+1 414-805-6805
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2008
University of Wisconsin School of Medicine & Public HealthClass of 2004
Certifications & Licensure
WI State Medical License 2013 - 2025
NY State Medical License 2008 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Clinical Trials
- A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Roles: Principal Investigator
Publications & Presentations
PubMed
- 4 citationsA phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin
Haematologica. 2024-09-01 - Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?Karen-Sue Carlson, Ashley Cunningham, Maximilian Stahl, Eric Winer, Laura C Michaelis
Acta Haematologica. 2024-01-01 - 2 citationsMiR-9-1 controls osteoblastic regulation of lymphopoiesis.Yongguang Zhang, Danfeng Lin, Yongwei Zheng, Yuhong Chen, Mei Yu
Leukemia. 2023-11-01
Abstracts/Posters
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Karen-Sue B. Carlson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I StudyKaren Carlson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant OutcomeKaren-Sue B. Carlson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
